Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Amyloidosis Channel is supported with funding from Prothena (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ISA 2020 | AL amyloidosis: Hot topics from ISA 2020

Vaishali Sanchorawala • 15 Sep 2020
ISA 2020
Amyloidosis Rare Diseases

Big topics for discussion at this year’s ISA meeting include measurable residual disease (MRD) assessment and hematological response measurement in AL amyloidosis. Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, discusses these hot topics from ISA 2020. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Vaishali Sanchorawala

Updated results with the bispecific antibody etentamig in patients with R/R AL amyloidosis
2:17
Updated results with the bispecific antibody etentamig in patients with R/R AL amyloidosis
Vaishali Sanchorawala • 8 Dec 2025
Cardiac safety of two Dara-VCd dosing schedules in newly diagnosed AL amyloidosis: AQUARIUS trial
5:43
Cardiac safety of two Dara-VCd dosing schedules in newly diagnosed AL amyloidosis: AQUARIUS trial
Vaishali Sanchorawala • 8 Dec 2025
Key agents of interest in the AL amyloidosis space with trial updates presented at ASH 2025
1:03
Key agents of interest in the AL amyloidosis space with trial updates presented at ASH 2025
Vaishali Sanchorawala • 8 Dec 2025
Amyloidosis Sessions: Highlights from ASH 2024
Amyloidosis Sessions: Highlights from ASH 2024
Vaishali Sanchorawala • 8 Dec 2024

Related Videos

Federated learning to train generative AI models for diagnosis & prognosis of hematological diseases
2:08
Federated learning to train generative AI models for diagnosis & prognosis of hematological diseases
Vaishali Sanchorawala • 7 Dec 2025
Initial results from the NEXICART-2 trial of BCMA-directed CAR-T (NXC-201) in R/R AL amyloidosis
2:25
Initial results from the NEXICART-2 trial of BCMA-directed CAR-T (NXC-201) in R/R AL amyloidosis
Vaishali Sanchorawala • 5 Dec 2025
Investigating novel therapeutic approaches for T-cell lymphoma
1:01
Investigating novel therapeutic approaches for T-cell lymphoma
Vaishali Sanchorawala • 8 Dec 2025
Phase II REVIVE trial: teclistamab plus daratumumab for high-risk smoldering multiple myeloma
3:45
Phase II REVIVE trial: teclistamab plus daratumumab for high-risk smoldering multiple myeloma
Vaishali Sanchorawala • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals